A Calgary biotech company using genetically modified safflower plants to make insulin will get US$2.5 million for the option to buy the rights to its end product. MannKind, a Los Angeles-area ...
Enrique Conterno, president, Lilly Diabetes said that an ultra-rapid acting insulin would be a "natural fit" in the company's growing portfolio. In September, the Lilly-Boehringer Ingelheim ...
Wockhardt Limited, the global pharmaceutical company, has submitted its indigenously developed fast-acting insulin analog, ASPARAPID, for regulatory approval with India’s Drugs Controller ...
These findings may usher in a new era in diabetes treatment without ... of hypoglycaemia and partly covering the need for fast-acting insulin at mealtime. The combination of these two features ...
Sanofi’s Admelog (insulin lispro) is approved in type 1 and type 2 diabetes as a follow-on drug to Humalog, a rapid-acting insulin ... way in which the FDA's new commissioner Scott Gottlieb ...
Drugmaker Wockhardt has approached the Drug Controller General of India (DCGI) seeking approvals for its fast-acting insulin analog, Aspart injection. The company’s Aspart insulin injection ...